Eidos Therapeutics

What Eidos Therapeutics does

Eidos Therapeutics is a clinical-stage, now commercially launching, biotechnology company developing genetically targeted therapies for rare diseases, with its principal focus on transthyretin amyloid cardiomyopathy (ATTR-CM). Its lead asset is acoramidis (marketed as Attruby), an oral small-molecule TTR protein stabilizer designed to bind and stabilize the transthyretin tetramer, preventing its dissociation and the subsequent misfolding into amyloid fibrils that accumulate in the myocardium. The FDA approved Attruby for adults with ATTR-CM in November 2024, supported by the ATTRibute-CM study demonstrating reductions in heart-related hospitalizations and mortality benefits. The company also lists NULIBRY (fosdenopterin), a treatment for a separate rare genetic condition, within its product portfolio via the BridgeBio organization.

Eidos was acquired by BridgeBio Pharma in 2020 and now operates as a subsidiary within BridgeBio's rare-disease platform, headquartered in Palo Alto, California. Its business model is a specialty/rare-disease pharma model: commercial revenue is generated from prescription drug sales of Attruby (US launch commenced late 2024) plus licensing/collaboration economics from the March 2024 exclusive European marketing partnership with Bayer AG, valued at up to $310 million. The company serves a narrowly defined patient population — adults with ATTR-CM, a rare, under-diagnosed, and life-threatening condition with median untreated survival of 3-5 years — through healthcare-professional channels, scientific conferences, and disease-education platforms (Trmatters.com, On Rare podcast). Customer concentration risk is structurally low at the prescriber/patient level but moderate-to-high at the commercialization partner level given dependence on Bayer for European reach.

The company employs 51-100 staff, consistent with a small commercial-stage biotech scaling medical affairs, sales, and launch infrastructure. Eidos is delisted from NASDAQ (former ticker EIDX), reflecting its 2020 acquisition by publicly traded BridgeBio (NASDAQ: BBIO).

Name

Eidos Therapeutics

Legal name

Eidos Therapeutics

Website

https://eidostx.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

Eidos Therapeutics is a BridgeBio subsidiary developing genetically targeted therapies for rare diseases, principally acoramidis (Attruby), an FDA-approved oral TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), commercialized in Europe via Bayer.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

akta.pro secondary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• Cardiomyopathy treatments
• TTR stabilizers
• Genetically targeted therapies
• Orphan drug development

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels3 records

Core offering

Eidos Therapeutics develops and commercializes genetically targeted pharmaceutical therapies for rare diseases. Its lead product, Attruby (acoramidis), is an oral transthyretin (TTR) protein stabilizer approved by the FDA for transthyretin amyloid cardiomyopathy (ATTR-CM), reducing heart-related hospitalizations. The company also markets NULIBRY (fosdenopterin) for another rare genetic condition under the BridgeBio Pharma portfolio.

Product overview

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, focuses on developing medicines for genetic diseases. The company offers a portfolio of pharmaceutical products including Attruby (acoramidis), a TTR protein stabilizer for ATTR-CM, and NULIBRY (fosdenopterin) for another genetic condition. The products address rare, under-diagnosed diseases with limited treatment options.

Differentiator

Problem solved

Functional benefit

Products and services

• Attruby (acoramidis) An oral transthyretin (TTR) protein stabilizer approved by the FDA for the treatment of adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM). It works by binding and stabilizing the TTR tetramer to prevent dissociation into amyloid fibrils, reducing heart-related hospitalizations. Marketed for patients with both wild-type and hereditary ATTR-CM, a rare and life-threatening disease.
• NULIBRY (fosdenopterin) An approved medication for a specific ultra-rare genetic condition, listed among BridgeBio/Eidos medicines. Used to treat patients with the corresponding rare genetic disease.

Quantifiable outcome

• Reduction in heart-related hospitalizations

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Bayer AGcoreChannel Partner/ Reseller/ Distributor · 1 March 2024Bayer AG secured exclusive European marketing rights for acoramidis from BridgeBio Pharma in a deal valued at up to $310 million. Bayer leverages its cardiovascular infrastructure to introduce the oral treatment across Europe. BridgeBio subsequently received FDA approval for Attruby (acoramidis) in November 2024.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Pfizer: Pfizer markets Vyndaqel/Vyndamax (tafamidis), the first FDA-approved TTR stabilizer for ATTR-CM. Eidos's Attruby (acoramidis) is a direct mechanistic and therapeutic competitor in the same patient population.
• Alnylam Pharmaceuticals: Alnylam develops Amvuttra (vutrisiran), an RNAi therapeutic targeting hepatic TTR production for ATTR-CM and hereditary ATTR amyloidosis. It competes in the same ATTR-CM disease space with a complementary gene-silencing mechanism.
• Ionis Pharmaceuticals: Ionis developed Tegsedi (inotersen), an antisense oligonucleotide targeting TTR for hereditary ATTR amyloidosis. It addresses the same transthyretin pathology through a different mechanism than Eidos's TTR stabilizer approach.

Others

• BridgeBio Pharma: BridgeBio Pharma is the parent company of Eidos Therapeutics following its 2020 acquisition. It serves as the operating parent across multiple genetic disease programs, including ATTR-CM via Eidos.
• Regeneron Pharmaceuticals: Regeneron develops genetic medicines and has cardiovascular and rare disease programs. As a large biotech with gene-silencing capabilities (via the Alnylam collaboration), it represents an adjacent player in the genetic medicine ecosystem relevant to Eidos.

Emerging players

• Prothena Corporation: Prothena develops monoclonal antibodies targeting amyloid diseases, including ATTR amyloidosis programs. It competes in the broader transthyretin amyloidosis therapeutic space with a distinct antibody-based mechanism.
• Intellia Therapeutics: Intellia is advancing in vivo CRISPR-based gene-editing therapies for transthyretin amyloidosis, including ATTR-CM. Its gene-editing approach targets TTR production at the DNA level and could disrupt the entire ATTR therapeutic class over time.

Broad incumbents

• AstraZeneca (Alexion): Through its Alexion rare disease franchise, AstraZeneca is a major player in genetic and rare diseases, including amyloidosis. It serves as a broad incumbent with adjacent rare disease commercial infrastructure that overlaps with Eidos's target market.
• Vertex Pharmaceuticals: Vertex has expanded beyond cystic fibrosis into rare genetic diseases through small-molecule and gene-editing approaches. It operates as a broad incumbent with capabilities and target patient populations relevant to Eidos's rare disease focus.
• Novo Nordisk: Novo Nordisk has historically been active in ATTR amyloidosis through Akcea-licensed assets and is a broad incumbent in cardiometabolic and rare diseases, positioning it as a comparable large-pharma peer in Eidos's disease space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/eidostx
• LinkedInlinkedin.com/company/18036080

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eidos Therapeutics